For research use only. Not for therapeutic Use.
BMS-986133（Cat No.:I023553）is an investigational drug developed by Bristol Myers Squibb, primarily being studied for its potential in treating autoimmune diseases, including rheumatoid arthritis and lupus. It is a selective inhibitor of the T-cell costimulatory protein CD40, which plays a critical role in immune cell activation and the inflammatory process. By targeting CD40, BMS-986133 aims to modulate the immune response, reducing inflammation and tissue damage. While early clinical trials have shown promising results, further research is needed to fully evaluate its safety, efficacy, and long-term outcomes for autoimmune conditions.
| Synonyms | BMS986133; BMS 986133; BMS-986133 |
| Molecular Formula | C26H23ClFN7O |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (10Z,18S)-18-(4-chloro-2-fluorophenyl)-6-(3-methyl-1,2,4-triazol-1-yl)-8-oxa-2,13,20,21-tetrazatetracyclo[12.6.1.13,7.015,19]docosa-1(20),3(22),4,6,10,14(21),15(19)-heptaene |
| InChI | InChI=1S/C26H23ClFN7O/c1-15-30-14-35(34-15)22-9-5-17-13-23(22)36-11-3-2-10-29-25-20-8-7-19(24(20)32-26(31-17)33-25)18-6-4-16(27)12-21(18)28/h2-6,9,12-14,19H,7-8,10-11H2,1H3,(H2,29,31,32,33)/b3-2-/t19-/m0/s1 |
| InChIKey | JLVFUZIDKWOYOX-AXMVSILFSA-N |
| SMILES | CC1=NN(C=N1)C2=C3C=C(C=C2)NC4=NC5=C(CC[C@H]5C6=C(C=C(C=C6)Cl)F)C(=N4)NC/C=C\CO3 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
